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Why in cachexia? 'None of us is as smart as all of us'
At the 2nd Cancer Cachexia Conference in Montreal (2014), several concerns came up. For instance, the participation of clinical staff and the possibility to reach out to everybody who wants to learn about the subject, and to those who are going to be the ones that judge and authorize therapies. Lets not forget the industry that founds the ongoing research; especially the nonprofit organizations feel much more at ease 'in the open'.
There is also a lot of heterogeneity when it comes to animal models: going to open source cachexia and getting in touch with hundreds of others scientists just with a click may solve the query.
Who is already using it?
Except in software, other areas are reaching out for it: the open source movement has increased transparency in biotechnology research. A good example is that of Cambia. It is 'an Australian non-profit organization focusing on open science, biology, and intellectual property'. Cambia's efforts to freely distribute scientific tools and techniques gave rise to the Biological Open Source (BiOS) Initiative. Through an open source biotechnology licence and material transfer agreement, BiOS seeks to establish freedom to operate for innovators.
A primary project of Cambia is the free full-text online patent search facility and knowledge resource, 'The Lens'; it allows free searching of almost 10 million full-text patent documents.
Another example is the open source search for the malaria cure (OSM). Veiled in secrecy and often complicated by patents and intellectual property issues, scientists are not always the best at sharing their results, at least not until they are published in peer reviewed journals-and sometimes after letting evidence fall under the table. This means that lots of data, especially 'negative' ones are hidden. Avoiding the loss of vast quantities of data is just one of the reasons behind the formation of the OSM team. The open source drug discovery project began in 2011, when Matthew Todd's lab received funding from the Medicines for Malaria Venture and then from the Australian Research Council in the form of a linkage grant. GlaxoSmithKline (GSK) had just published a revolutionary paper 2 containing potential antimalarial medicines and placed the information into the public domain. Those open GSK data were the starting of the OSM project and led to the team synthesizing and evaluating three different series of compounds. 
L E T T E R T O T H E E D I T O R
The use of open source for drug discovery
Because no drug has ever been discovered using an open source approach, it is difficult to be certain about how this would work. However, it seems likely that the biggest impact of the open approach would be in the early phases before clinical trials have started. Open methods could also have an impact on the process chemistry phase, in creating an efficient chemical synthesis on a large scale. [3] [4] [5] One negative aspect to bear in mind is that open work cannot be patented, because there can be no delays to release of data. Open source drug discovery must operate without patents. The hypothesis is that through working in an open mode, research and development costs are reduced, and research is accelerated. This offsets the lack of capital support for the project. Costs of clinical trials and product registration would have to be sourced from government and non-government organizations. It has to be pointed out, however, that some large pharmaceutical companies (GSK and Novartis) (GSK has even an 'Open Lab' in Tres Cantos, Spain; it provides an opportunity for visiting scientists from leading international institutions to work at the campus for a dedicated period of time, accessing GSK drug discovery expertise as part of an integrated team to discover new medicines.) have used open source. Founding comes from elsewhere, for example the Bill and Melinda Gates Foundation and the Global Fund, and even large multinational coalitions. Interest in cachexia research is growing everyday, and because wasting is present in many diseases, such as cancer, AIDS, COPD, and chronic heart disease, it attracts researchers and pharmaceutical companies; therefore open source should be encouraged (Figure 1) . 6, 7 Open source tools 
